SMA Newsroom

ResearchDec 1, 2018

Scholar Rock Reports Preclinical Data on the Therapeutic Benefit of SRK-015 in Models of SMA

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the publication, “Specific Inhibition of Myostatin Activation is Beneficial in Mouse Models of SMA Therapy” in the peer-reviewed journal Human Molecular Genetics.